Patient Stories

Stories Directly from YUTIQ Patients

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is designed to be a long-lasting option to treat uveitis affecting the back of the eye. Watch how patients living with uveitis affecting the posterior segment explain their journey with uveitis and their personal experience with YUTIQ treatment. These stories are the individual experience of each patient shown. Results may vary among patients.

Christine’s YUTIQ Journey

After visiting multiple doctors who couldn’t pinpoint her condition, Christine found Dr. Dayani, who diagnosed her with uveitis affecting the posterior segment and introduced YUTIQ as a possible solution. Before, Christine’s bi-monthly injections were time-consuming and anxiety-provoking, and now she hasn’t needed another injection in over two years.

David’s YUTIQ Journey

Frequent eye appointments became burdensome for David, then he learned about YUTIQ and its ability to treat his uveitis for up to three years. Now, David’s vision has vastly improved, the inflammation has subsided, and he just goes in for his routine three-month follow-up appointments—serving as the only reminder of his eye condition.

See David’s eye doctor talk about his procedure here.

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full US Prescribing Information.
    Alimera Sciences, Inc. June 2023.

References

  1. What is Uveitis?. Prevent Blindness. Updated June 21, 2021. Accessed November 28, 2023. 

https://preventblindness.org/wp-content/uploads/2021/06/FS119-Uveitisshort.pdf